Study S002357

Addition of Liraglutide to Overweight Patients With Type 2 Diabetes Treated With Multiple Daily Insulin Injections (MDI) With Inadequate Glycaemic Control

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT02113332
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 124
Start: 2013-01
Primary completion: 2014-08
Lead sponsor: Vastra Gotaland Region
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:Liraglutide; DRUG:Placebo
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2012-001941-42

Registered primary outcomes

Change in HbA1c from baseline to week 24. [Baseline, week 24]

Linked records (9)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0022655	Effect of liraglutide on markers of insulin production in persons with type 2 diabetes treated with multiple daily insulin injections. Westman K, Journal of diabetes and its complications	2022	Randomized trial	PMID 35101325 DOI	cites EudraCT:2012-001941-42
R0021458	Effect of Liraglutide on Times in Glycaemic Ranges as Assessed by CGM for Type 2 Diabetes Patients Treated With Multiple Daily Insulin Injections. Sofizadeh S, Diabetes therapy : research, treatment and education of diabetes and related disorders	2019	Randomized trial	PMID 31564026 DOI	cites EudraCT:2012-001941-42
R0025116	Variables associated with HbA1c and weight reductions when adding liraglutide to multiple daily insulin injections in persons with type 2 diabetes (MDI Liraglutide trial 3). Dahlqvist S, BMJ open diabetes research & care	2018	Randomized trial	PMID 29527308 DOI	cites EudraCT:2012-001941-42
R0023744	Design and methods of a randomised double-blind trial of adding liraglutide to control HbA1c in patients with type 2 diabetes with impaired glycaemic control treated with multiple daily insulin injections (MDI-Liraglutide trial). Lind M, Primary care diabetes	2015	Randomized trial	PMID 25175385 DOI	cites ClinicalTrials.gov:NCT02113332; registry reference DERIVED:25175385
R0026157	Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial). Lind M, BMJ (Clinical research ed.)	2015	Randomized trial	PMID 26512041 DOI	cites EudraCT:2012-001941-42
R0017610	Incretin therapy and its effect on body weight in patients with diabetes. Lind M, Primary care diabetes	2012	Narrative review	PMID 22613745 DOI	registry reference BACKGROUND:22613745
R0021844	Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction. Lind M, Primary care diabetes	2012	Other	PMID 22015237 DOI	registry reference BACKGROUND:22015237
R0025739	Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Pratley RE, Lancet (London, England)	2010	Randomized trial	PMID 20417856 DOI	registry reference BACKGROUND:20417856
R0019554	The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus. Pi-Sunyer FX, Postgraduate medicine	2009	Narrative review	PMID 19820278 DOI	registry reference BACKGROUND:19820278